Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma

Ka Lung Wu, Meral Beksac, Jan Van Droogenbroeck, Sergio Amadori, Sonja Zweegman, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
Original languageEnglish
Pages (from-to)1722-1723
Number of pages2
JournalHaematologica
Volume91
Issue number12
Publication statusPublished - Dec 2006

Cite this

Wu, Ka Lung ; Beksac, Meral ; Van Droogenbroeck, Jan ; Amadori, Sergio ; Zweegman, Sonja ; Sonneveld, Pieter. / Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. In: Haematologica. 2006 ; Vol. 91, No. 12. pp. 1722-1723.
@article{6c2f5b462ac14d5ca6cd92c53b155230,
title = "Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma",
abstract = "Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.",
keywords = "Arsenic trioxide, Multiple myeloma, Single nucleotide polymorphisms",
author = "Wu, {Ka Lung} and Meral Beksac and {Van Droogenbroeck}, Jan and Sergio Amadori and Sonja Zweegman and Pieter Sonneveld",
year = "2006",
month = "12",
language = "English",
volume = "91",
pages = "1722--1723",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

Wu, KL, Beksac, M, Van Droogenbroeck, J, Amadori, S, Zweegman, S & Sonneveld, P 2006, 'Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma' Haematologica, vol. 91, no. 12, pp. 1722-1723.

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. / Wu, Ka Lung; Beksac, Meral; Van Droogenbroeck, Jan; Amadori, Sergio; Zweegman, Sonja; Sonneveld, Pieter.

In: Haematologica, Vol. 91, No. 12, 12.2006, p. 1722-1723.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma

AU - Wu, Ka Lung

AU - Beksac, Meral

AU - Van Droogenbroeck, Jan

AU - Amadori, Sergio

AU - Zweegman, Sonja

AU - Sonneveld, Pieter

PY - 2006/12

Y1 - 2006/12

N2 - Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.

AB - Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.

KW - Arsenic trioxide

KW - Multiple myeloma

KW - Single nucleotide polymorphisms

M3 - Article

VL - 91

SP - 1722

EP - 1723

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -